Analyzing bioAffinity Technologies (BIAF) and The Competition

bioAffinity Technologies (NASDAQ:BIAF) is one of 39 publicly-traded companies in the “Commercial physical research” industry, but how does it compare to its peers? We will compare bioAffinity Technologies to similar companies based on the strength of its analyst recommendations, dividends, valuation, risk, earnings, institutional ownership and profitability.

Risk and Volatility

bioAffinity Technologies has a beta of 3.93, meaning that its stock price is 293% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ peers have a beta of 6.02, meaning that their average stock price is 502% more volatile than the S&P 500.

Profitability

This table compares bioAffinity Technologies and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-313.34%	-107.20%	-84.10%
bioAffinity Technologies Competitors	-249.68%	-18.55%	-11.34%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for bioAffinity Technologies and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0	0	0	0	N/A
bioAffinity Technologies Competitors	50	812	1297	31	2.60

As a group, “Commercial physical research” companies have a potential upside of 8.31%. Given bioAffinity Technologies’ peers higher possible upside, analysts clearly believe bioAffinity Technologies has less favorable growth aspects than its peers.

Institutional and Insider Ownership

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 52.6% of shares of all “Commercial physical research” companies are owned by institutional investors. 44.3% of bioAffinity Technologies shares are owned by insiders. Comparatively, 17.0% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares bioAffinity Technologies and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
bioAffinity Technologies	$2.53 million	-$7.94 million	-3.08
bioAffinity Technologies Competitors	$1.55 billion	$101.44 million	-0.36

bioAffinity Technologies’ peers have higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

bioAffinity Technologies peers beat bioAffinity Technologies on 8 of the 9 factors compared.

About bioAffinity Technologies

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.